Dermata Therapeutics (NASDAQ:DRMA) and Structure Therapeutics (NASDAQ:GPCR) Head to Head Survey

Structure Therapeutics (NASDAQ:GPCR) and Dermata Therapeutics (NASDAQ:DRMA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, dividends, valuation and profitability.

Risk and Volatility

Structure Therapeutics has a beta of -1.5, suggesting that its share price is 250% less volatile than the S&P 500. Comparatively, Dermata Therapeutics has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500.

Profitability

This table compares Structure Therapeutics and Dermata Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-24.91%	-23.67%
Dermata Therapeutics	N/A	-127.91%	-105.05%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Structure Therapeutics and Dermata Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2	1	12	3	2.89
Dermata Therapeutics	1	0	1	0	2.00

Structure Therapeutics currently has a consensus price target of $110.55, suggesting a potential upside of 128.02%. Dermata Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 651.88%. Given Dermata Therapeutics’ higher probable upside, analysts clearly believe Dermata Therapeutics is more favorable than Structure Therapeutics.

Earnings & Valuation

This table compares Structure Therapeutics and Dermata Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20 million	($0.87)	-55.72
Dermata Therapeutics	N/A	N/A	-$7.56 million	($5.31)	-0.25

Structure Therapeutics is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 8.7% of Dermata Therapeutics shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by company insiders. Comparatively, 21.9% of Dermata Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Structure Therapeutics beats Dermata Therapeutics on 7 of the 12 factors compared between the two stocks.

About Structure Therapeutics

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

About Dermata Therapeutics

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.